Skip to content

AACR, NCI and EORTC to Host Molecular Targets and Cancer Therapeutics International Conference

November 9, 2009

PHILADELPHIA – Scientists and industry leaders from around the world will gather in Boston Nov. 14-19, 2009, for the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, which will feature groundbreaking information on important cancer therapies in development.

“Cancer is a complex disease and to treat it effectively we need a greater understanding of the activity that takes place at the molecular level,” said Lewis Cantley, Ph.D., director of the cancer center at Beth Israel Deaconess Medical Center and one of the scientific committee chairpersons of the conference. “The research presented at this conference will bring us closer to that understanding.”

Experts from the world’s leading cancer centers and pharmaceutical companies will discuss innovations in drug development, target selection and the impact of new discoveries in molecular and cellular biology.

Understanding the pathways and mechanisms that cause cancer and regulate the biological behavior of tumor cells has already led to the development of numerous new agents. This conference, now in its second decade, has been organized to reflect the many recent advances in the early development of promising new compounds.

During the conference, the American Association for Cancer Research will host several press briefings: “Drugs in the Pipeline,” “Emerging Therapies in Pancreatic Cancer” and “Markers of Prognosis.”

For the latest information on the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics International Conference, follow the AACR on Twitter using the hashtag #AACRTargets09

Subscribe to the AACR RSS News Feed

# # #

The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 30,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and nearly 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowship and career development awards. The AACR Annual Meeting attracts more than 16,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. The AACR publishes six major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists. CR provides a forum for sharing essential, evidence-based information and perspectives on progress in cancer research, survivorship and advocacy.

About NCI

The National Cancer Institute (NCI) leads the National Cancer Program and the NIH effort to dramatically reduce the burden of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI Web site at or call NCI’s Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).


The European Organisation for Research and Treatment of Cancer (EORTC) is an international association under Belgian law created in 1962.

The aims of the EORTC are to develop, conduct, coordinate, and stimulate translational and clinical cancer research in Europe to improve the management of cancer and related problems by increasing both survival and patient quality of life. The ultimate goal of the EORTC is to establish state-of-the-art cancer treatment to improve survival rate, quality of life and quality of care for all patients with cancer.

The EORTC is primarily devoted to high-quality clinical research to establish optimal therapeutic strategies via large multi-center clinical studies in a multidisciplinary approach leading to state-of-the-art treatment.

In line with the increasingly important role of functional imaging in trials involving translational research and having endpoints linked to biological markers, the EORTC Board has decided to establish an Imaging Group to drive the development of treatment strategies tailored to the biological characteristics of a particular tumor.

EORTC Headquarters has instituted quality assurance in radiotherapy (QART), and these measures have resulted in measurably significant improvement in treatment delivery and patient outcome in radiotherapy.

The EORTC has initiated a European tumor bank project to improve and harmonize the histological review and to promote translational research in EORTC trials.

The EORTC Headquarters’ Early Project Optimization Department (EPOD) lends support and methodological expertise to the EORTC groups for all new projects.

A Network of Core Institutions (NOCI) has been formed as part of the overall EORTC strategy. NOCI is based on core recruiting academic centers across Europe, specifically apt to develop projects with important translational research components.

EORTC Headquarters comprises about 160 staff members (15 nationalities) including medical doctors, statisticians, PhD’s, quality of life specialists, scientific and administrative staff, computer specialists and research fellows.

All EORTC research projects and clinical studies are peer reviewed and have to be approved by the relevant EORTC Committees.

An Academic Research Fund has been created to allocate support for clinical trials of excellence submitted to the Board.

Over 6,000 new patients are treated each year according to EORTC protocols.

For further information see:

Media Contact:

Jeremy Moore


In Boston, Nov. 15-19:

(617) 954-3042

No comments yet

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: